Ovid Therapeutics Inc.

Ovid Therapeutics Inc. Estimates – NASDAQ:OVID
TradingView · 23 Oct 2026
OVID Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 8.76% - Guidance Downgrade Alert
https://www.dars.gov.et/ · 21 Oct 2026
OVID Initiates Coverage On Wolfe Research -- Rating Set to Outpe
GuruFocus · 15 Oct 2026
Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald
TipRanks · 09 Oct 2026
OVID Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov
GuruFocus · 09 Oct 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.